Kevin Luk, PhD (@k_luk2) 's Twitter Profile
Kevin Luk, PhD

@k_luk2

Scientist @Excisionbio ◼️ @Concordia_MN and @UMassChan alum ◼️ Whiskey loving liberal scientist. Opinions are my own.

ID: 428694393

calendar_today05-12-2011 02:26:11

605 Tweet

88 Followers

79 Following

Dr. Jooyoung Lee (@jooyounglee10) 's Twitter Profile Photo

THANK YOU for coming to my dissertation seminar today🎓 It has been a wonderful journey working with incredible friends and colleagues 🙏🏻 I am very grateful for all your support throughout my journey 🎉 Thank you so much again!!!!🥳 #PhDone #PhD #CRISPR #antiCRISPR #DrLee

THANK YOU for coming to my dissertation seminar today🎓
It has been a wonderful journey working with incredible friends and colleagues 🙏🏻 I am very grateful for all your support throughout my journey 🎉 Thank you so much again!!!!🥳
#PhDone #PhD #CRISPR #antiCRISPR #DrLee
The Nobel Prize (@nobelprize) 's Twitter Profile Photo

BREAKING NEWS: The 2020 #NobelPrize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna “for the development of a method for genome editing.”

BREAKING NEWS: 
The 2020 #NobelPrize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna “for the development of a method for genome editing.”
Bernie Sanders (@berniesanders) 's Twitter Profile Photo

Yesterday, Trump took full credit for the 30,000 Dow Jones, but took zero credit for 260,000 Americans who died from COVID, 40 million who face eviction or 26 million who don't have enough food to eat on Thanksgiving. No, Mr. President. The stock market is not the economy.

bioRxiv (@biorxivpreprint) 's Twitter Profile Photo

Optimization of NLS Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells biorxiv.org/cgi/content/sh… #bioRxiv

Kevin Luk, PhD (@k_luk2) 's Twitter Profile Photo

Preprint of my work on improved CRISPR-Cas12a gene editing. Great read for anyone who is interested in gene editing in general.

Kevin Luk, PhD (@k_luk2) 's Twitter Profile Photo

I am defending my phD thesis in 8 days. Also, I have accepted a scientist position at Excision BioTherapeutics. I am incredibly excited for the next stage of my career! Please reach out to me if you are interested in attending so that I can send you the Zoom meeting link.

I am defending my phD thesis in 8 days. Also, I have accepted a scientist position at Excision BioTherapeutics. I am incredibly excited for the next stage of my career! 
Please reach out to me if you are interested in attending so that I can send you the Zoom meeting link.
GEN Biotechnology (@genbiotechjrnl) 's Twitter Profile Photo

Issue #3 is live and free for a limited time! -#AI and #DrugDiscovery -The 'compleat' human #genome -Tackling racial disparities in biotech Tendai Chisowa -Single cell technologies Kiana Aran -Base editing via single AAV ErikSontheimerLab liebertpub.com/toc/genbio/1/3

Issue #3 is live and free for a limited time!
-#AI and #DrugDiscovery
-The 'compleat' human #genome
-Tackling racial disparities in biotech <a href="/TendaiChisowa/">Tendai Chisowa</a>
-Single cell technologies <a href="/kiana_aran/">Kiana Aran</a>
-Base editing via single AAV <a href="/ESontheimerLab/">ErikSontheimerLab</a> 
liebertpub.com/toc/genbio/1/3
GEN Biotechnology (@genbiotechjrnl) 's Twitter Profile Photo

Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells (Luk et al.) UMass Chan Medical School #CRISPR #GeneEditing liebertpub.com/doi/10.1089/ge…

Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells (Luk et al.) <a href="/UMassChan/">UMass Chan Medical School</a>

#CRISPR #GeneEditing 

liebertpub.com/doi/10.1089/ge…
Kevin Luk, PhD (@k_luk2) 's Twitter Profile Photo

My new epub is online in GEN Biotechnology. We improved CRISPR-Cas12a genome editing in human primary cells via NLS architecture optimization. The issue also features a great paper from ErikSontheimerLab on a single AAV vector for in vivo delivery of Nme2-ABE liebertpub.com/doi/10.1089/ge…

Genetic Engineering & Biotechnology News (@genbio) 's Twitter Profile Photo

In a study published in GEN Biotechnology, Scot Wolfe, PhD, and his UMass Chan Medical School team, increased Cas12a’s on-target #geneediting rate to nearly 100% by engineering the configuration of the enzyme’s nuclear localization signal. Read more: ow.ly/NUXG50JCCkP #CRISPR #CRISPRCas9

In a study published in <a href="/GENBiotechJrnl/">GEN Biotechnology</a>, Scot Wolfe, PhD, and his <a href="/UMassChan/">UMass Chan Medical School</a> team, increased Cas12a’s on-target #geneediting rate to nearly 100% by engineering the configuration of the enzyme’s nuclear localization signal. Read more: ow.ly/NUXG50JCCkP #CRISPR #CRISPRCas9
Excision BioTherapeutics (@excisionbio) 's Twitter Profile Photo

Congratulations to Excision’s Kevin Luk Kevin Luk, PhD on Genetic Engineering & Biotechnology News publication while in Scot Wolfe’s lab UMass Chan Medical School increasing gene editing activity through improved NLS framework liebertpub.com/doi/10.1089/ge… #CRISPR #CRISPRCas9

Congratulations to <a href="/Excision/">Excision</a>’s Kevin Luk <a href="/K_Luk2/">Kevin Luk, PhD</a> on <a href="/GENbio/">Genetic Engineering & Biotechnology News</a> publication while in Scot Wolfe’s lab <a href="/UMassChan/">UMass Chan Medical School</a> increasing gene editing activity through improved NLS framework

liebertpub.com/doi/10.1089/ge…
#CRISPR #CRISPRCas9
Excision BioTherapeutics (@excisionbio) 's Twitter Profile Photo

Today Excision announced the dosing of our first participant in EBT-101 Phase 1/2 trial evaluating EBT-101 as a potential cure for HIV. Read our press release: bit.ly/3xlVIJV

Today Excision announced the dosing of our first participant in EBT-101 Phase 1/2 trial evaluating EBT-101 as a potential cure for HIV.

Read our press release: bit.ly/3xlVIJV
Excision BioTherapeutics (@excisionbio) 's Twitter Profile Photo

Today Excision announced that we have been awarded the California Institute for Regenerative Medicine Grant, to support our ongoing Phase 1/2 trial evaluating EBT-101 as a potential cure for HIV. Red our press release: bit.ly/3UQ4sSw #GeneEditing #CRISPR #HIV

Today Excision announced that we have been awarded the California Institute for Regenerative Medicine Grant, to support our ongoing Phase 1/2 trial evaluating EBT-101 as a potential cure for HIV. 
 
Red our press release: bit.ly/3UQ4sSw

#GeneEditing #CRISPR #HIV